NDA 202324 · Pf Prism Cv
Inlyta
Axitinib · Oral · Kinase Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Jul 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Jan 27, 2012
Approved uses
3
Original approval plus efficacy supplements
Registered trials
209
20 Phase 3, 29 recruiting
FAERS reports
19,549
12,971 serious, 3,948 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 15, 2026.
Axitinib is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) • in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) • as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) 1.1 First-Line Advanced Renal Cell Carcinoma Axitinib in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Axitinib in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced RCC. 1.2 Second-Line Advanced Renal Cell Carcinoma Axitinib as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.
Mechanism: Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograft mouse models.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 22, 2022 Supplement 14 · Efficacy LabelLetter
- Jun 4, 2020 Supplement 11 · Efficacy · priority review LabelLetter
- Jan 27, 2012 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
2 products under this application
- INLYTA · AXITINIB 1MG · TABLET, ORAL · Prescription · TE AB
- INLYTA · AXITINIB 5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Axitinib" as an intervention, any sponsor and status, largest first.
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- CARE1 Pragmatic Clinical TrialPivotal-lookingRecruiting
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT06364631 · 1,250 participants (planned) · Start Apr 12, 2024 · Primary completion May 5, 2032
Drug: Nivolumab; Ipilimumab and 4 more · For: Metastatic Kidney Cancer; Metastatic Kidney Carcinoma
Sites: Vienna, Austria; Brno, Czechia; Hradec Králové, Czechia · 46 sites in all
- Molecularly Tailored Therapy in Advanced Pancreatic CancerPivotal-lookingNot yet recruiting
Herlev HospitalAcademic, hospital or other
NCT07802418 · 1,200 participants (planned) · Start Oct 2026 · Primary completion Jun 2031
Drug: Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy and 1 more · For: Pancreatic Cancer
Sites: Aalborg, Denmark; Aarhus, Denmark; Herlev, Denmark · 4 sites in all
- A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyPivotal-lookingRecruiting
Ocular Therapeutix, Inc.Industry
NCT07235085 · 930 participants (planned) · Start Nov 17, 2025 · Primary completion Mar 2027
Drug: Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24; Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 · For: Non-Proliferative Diabetic Retinopathy
Sites: Hagerstown, Maryland
- A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02684006 · 886 participants · Start Mar 23, 2016 · Primary completion Aug 31, 2023
Drug: Avelumab (MSB0010718C); Axitinib (AG-013736) and 1 more · For: Renal Cell Cancer
Sites: Daphne, Alabama; Mobile, Alabama; Beverly Hills, California · 270 sites in all
- Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02853331 · 861 participants · Start Sep 16, 2016 · Primary completion Oct 18, 2018
Drug: Pembrolizumab; Axitinib and 1 more · For: Renal Cell Carcinoma
Ocular Therapeutix, Inc.Industry
NCT07516132 · 850 participants (planned) · Start Apr 27, 2026 · Primary completion Aug 1, 2030
Drug: OTX-TKI · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Bakersfield, California; Santa Barbara, California; Waterford, Connecticut · 8 sites in all
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationPivotal-lookingActive, not recruiting
Ocular Therapeutix, Inc.Industry
NCT06495918 · 825 participants (planned) · Start Nov 27, 2024 · Primary completion Jan 8, 2027
Drug: OTX-TKI; Aflibercept and 1 more · For: Neovascular Age-related Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 97 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death2,699
- diarrhoea2,594
- fatigue2,123
- hypertension1,331
- neoplasm progression1,324
- disease progression1,211
- off label use1,207
- nausea1,145
- decreased appetite1,094
- dysphonia1,013
- blood pressure increased855
- weight decreased806
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 18 |
| 2010 | 32 |
| 2011 | 28 |
| 2012 | 569 |
| 2013 | 1,060 |
| 2014 | 1,157 |
| 2015 | 1,094 |
| 2016 | 814 |
| 2017 | 766 |
| 2018 | 697 |
| 2019 | 1,160 |
| 2020 | 2,413 |
| 2021 | 2,270 |
| 2022 | 2,688 |
| 2023 | 1,907 |
| 2024 | 1,429 |
| 2025 | 889 |
| 2026 | 557 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Inlyta (Axitinib)
2024 spending
$439M
Beneficiaries
4,465
24,770 claims
Per beneficiary
$98,299
$238.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $263,233,497 |
| 2021 | $376,064,185 |
| 2022 | $417,577,746 |
| 2023 | $466,771,314 |
| 2024 | $438,904,956 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI, Plimack ER, Stus V, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ, Penkov K, Haanen J, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto R, Sousa LG, Feng L, et al. · J Clin Oncol 2023 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A, Besiroglu B, Adams A, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacological interventions for intraplaque neovascularization in atherosclerosis.
Ugusman A, Hisam NSN, Othman NS, et al. · Pharmacol Ther 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.
Rini BI, Plimack ER, Stus V, et al. · Nat Med 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Pf Prism Cv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.